MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
A phase 3 trial of Elranatamab, Elotuzumab, Pomalidomide in multiple myeloma, run by Pfizer, now recruiting.
Overview
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) is a phase 3 interventional study registered as NCT06152575 by Pfizer, with 492 participants planned, started 2024-02-08 and due to reach its primary completion in 2026-08-30. Interventions recorded: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Elotuzumab, Carfilzomib, Pomalidomide, Bortezomib.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Elranatamab, Pomalidomide, Dexamethasone, Pfizer (incl. Seagen).
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Elranatamab, Bortezomib, Dexamethasone, Pfizer (incl. Seagen).
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.